| Name | Title | Contact Details |
|---|---|---|
Ling Zeng |
Chief Legal and Administrative Officer | Profile |
Jeffrey Kopacz |
Vice President, Intellectual Property | Profile |
RoosterBio is a Maryland-based biotechnology company founded in 2012 and focused on the simplification of translating Cell Therapy and Tissue Engineering technologies into the clinic and onto the market. Regenerative Medicine is showing great promise in the clinic, but the cost, availability, and standardization of the cellular materials from which researchers can perform experiments and clinical trials is holding the field back.
Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Novan is a clinical-stage drug development company focused on topical delivery of nitric oxide. The company`s proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms. Novan is currently developing innovative, first-in-class therapies for the field of dermatology.